Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 8/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25472689 | 0.94 | TDP1 (0.47) | GPR35LMNATDP1MEN1KMT2A | |
| SCHEMBL19935419 | 0.88 | GPR35 (0.67) | GPR35LMNATDP1MEN1KMT2A | |
| SCHEMBL27108981 | 0.83 | GPR35 (0.49) | GPR35LMNATDP1MEN1KMT2A | |
| SCHEMBL19935516 | 0.83 | GPR35 (0.49) | GPR35LMNATDP1MEN1KMT2A | |
| SCHEMBL25472686 | 0.83 | GPR35 (0.60) | GPR35LMNATDP1MEN1KMT2A | |
| SCHEMBL145538 | 0.81 | GPR35 (0.79) | GPR35LMNATDP1MEN1KMT2A | |
| SCHEMBL19976066 | 0.81 | GPR35 (0.79) | GPR35LMNATDP1MEN1KMT2A | |
| SCHEMBL30413495 | 0.81 | GPR35 (0.79) | GPR35LMNATDP1MEN1KMT2A | |
| SCHEMBL24600022 | 0.81 | GPR35 (0.47) | GPR35LMNATDP1MEN1KMT2A | |
| SCHEMBL25584298 | 0.81 | GPR35 (0.67) | GPR35LMNATDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067635-A1 | CROMOLYN DERIVATIVES AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION | 2024-02-29 | — | — | US | disclosed |
| US-20240067635-A1 | CROMOLYN DERIVATIVES AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION | 2024-02-29 | — | — | US | disclosed |
| EP-3506894-B1 | MACROPHAGES/MICROGLIA IN NEURO-INFLAMMATION ASSOCIATED WITH NEURODEGENERATIVE DISEASES | MASSACHUSETTS GEN HOSPITAL (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230226017-A1 | METHODS OF TREATING A CORONAVIRUS INFECTION | MASSACHUSETTS GEN HOSPITAL (US) | 2023-07-20 | — | — | US | disclosed |
| US-11679095-B2 | Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases | THE GENERAL HOSPITAL CORPORATION (US) | 2023-06-20 | — | — | US | disclosed |
| US-11679095-B2 | Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases | THE GENERAL HOSPITAL CORPORATION (US) | 2023-06-20 | — | — | US | disclosed |
| US-20230149345-A1 | METHODS OF TREATMENT OF CORONAVIRUS-INDUCED INFLAMMATION CONDITIONS | THE GENERAL HOSPITAL CORPORATION | 2023-05-18 | — | — | US | disclosed |
| US-20220218652-A1 | METHODS OF TREATING CYTOKINE RELEASE SYNDROME | AZTHERAPIES, INC. | 2022-07-14 | — | — | US | disclosed |
| WO-2022146914-A1 | CROMOLYN DERIVATIVES AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 2022-07-07 | — | — | WO | disclosed |
| US-20210059977-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | THE GENERAL HOSPITAL CORPORATION | 2021-03-04 | — | — | US | disclosed |
| WO-2019199776-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF AMYOTROPIC LATERAL SCLEROSIS AND RELATED DISORDERS | THE GENERAL HOSPITAL CORPORATION (US) | 2019-10-17 | — | — | WO | disclosed |
| US-20190240194-A1 | MACROPHAGES/MICROGLIA IN NEURO-INFLAMMATION ASSOCIATED WITH NEURODEGENERATIVE DISEASES | THE GENERAL HOSPITAL CORPORATION | 2019-08-08 | — | — | US | disclosed |
| WO-2018045217-A1 | MACROPHAGES/MICROGLIA IN NEURO-INFLAMMATION ASSOCIATED WITH NEURODEGENERATIVE DISEASES | THE GENERAL HOSPITAL CORPORATION (US) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190240194-A1 | MACROPHAGES/MICROGLIA IN NEURO-INFLAMMATION ASSOCIATED WITH NEURODEGENERATIVE DISEASES | CD68, PRNP, HTT | GPR35 1528/4885LMNA 755/4885TDP1 3376/4885 |
| US-20240067635-A1 | CROMOLYN DERIVATIVES AND USES THEREOF | PRNP, HTT, CLN6 | GPR35 1991/4885LMNA 111/4885TDP1 978/4885 |
| US-11679095-B2 | Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases | CD68, PRNP, HTT | GPR35 1528/4885LMNA 755/4885TDP1 3376/4885 |
| US-20220218652-A1 | METHODS OF TREATING CYTOKINE RELEASE SYNDROME | CMKLR1, CMKLR2, GSS | GPR35 393/4885LMNA 3211/4885TDP1 3763/4885 |
| US-20230149345-A1 | METHODS OF TREATMENT OF CORONAVIRUS-INDUCED INFLAMMATION CONDITIONS | C3AR1, IL5, C5 | GPR35 359/4885LMNA 3678/4885TDP1 4796/4885 |
| US-20230226017-A1 | METHODS OF TREATING A CORONAVIRUS INFECTION | CPA3, CMA1, ACE2 | GPR35 1712/4885LMNA 2521/4885TDP1 3569/4885 |
| US-20210059977-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | CLN6, PRNP, RTN3 | GPR35 3648/4885LMNA 66/4885TDP1 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.